Picture the call every site director dreads: the FDA is arriving tomorrow. Under the traditional model, that notification triggers a 3-to-6-day endurance event — staff rotations, conference room logistics, document retrieval queues, and a PI who cancels clinic for half the week. Now picture the same call, except the investigator is staying for one day. Every document request, every system access, every response to a verbal query has to land in hours, not days. That is the operational reality the FDA’s newly launched one-day inspectional assessment pilot creates — and most sites are not set up to survive it cleanly.
The FDA launched its One-Day Inspectional Assessments in April 2026 under the BRIDGE Project — Better Regulatory Inspections for Dynamic Government Efficiency. The stated purpose is efficiency: redirect limited investigator resources toward higher-risk sites by clearing lower-complexity sites faster. Given that FDA conducted 1,065 total inspections in fiscal year 2023 — still 36% below the 1,671 inspections performed in FY2019 — the capacity argument is real. But the operational implications for investigator sites in clinical trials are being badly underread by both sponsors and CROs.
What “One Day” Actually Compresses
The traditional inspection rhythm at a clinical site has a tolerance for friction built into it. Day one is usually an opening meeting, a walk-through, and the first document requests. Days two and three are where the real review happens — source documentation against CRFs, ICF version control, IP accountability logs, deviation and CAPA files. If the coordinator pulls the wrong binder on day one, there is time to correct it. The standard inspection window of three to six days exists precisely because regulatory review of trial records is not a linear process. Inspectors follow threads. A discrepancy in a visit date opens a chain of source document requests. There is give in the timeline.
One day eliminates that give entirely. What used to be a staged document production becomes a single-window retrieval exercise. The eISF has to be navigable by someone who has never opened it before, without a coordinator walking them through the folder logic. Every deviation log has to be current, reconciled, and self-explanatory. Informed consent version histories have to be indexed so cleanly that the inspector can confirm subject-by-subject enrollment chronology without asking a follow-up question. Sites that have been running TMF completeness in the 70-80% range — acceptable in a mid-monitoring-cycle world — will not survive a one-day review that hits the same artifacts a full inspection would.
The counterintuitive read here is that a shorter inspection is not a lighter inspection. The FDA is not reducing scrutiny — it is concentrating it. A one-day assessment that surfaces a critical finding is still a critical finding. The 483 observation goes in the same place. The CAPA requirement lands on the same desk. Compression of time does not compress consequence.
The Documentation Gap Sponsors Aren’t Funding
Here is where this moves from a compliance conversation to an economics conversation. Across our network at CliniBiz, the most common TMF deficiency we see at mid-trial monitoring visits involves currency — documents that exist but aren’t filed, filed but not indexed, or indexed under a version that doesn’t match the active protocol amendment. A site running three concurrent studies with one coordinator often has a TMF that is six to eight weeks behind real-time. Under a traditional inspection model, a motivated CRA can run a completeness sprint in the two weeks before a known inspection window and close most of those gaps. Under a one-day model, there is no sprint window — the assessment can arrive with minimal notice and the TMF has to already be at inspection readiness.
That operational requirement has a cost that sponsor budgets are not currently absorbing. The staffing model for most investigator sites still treats TMF maintenance as a background task — something the CRC does between visits and enrollment calls. Bringing a site’s documentation to continuous inspection-ready status requires either dedicated TMF support or a significantly higher coordinator FTE budget. Neither appears as a line item in most clinical trial agreements. The FDA’s clinical research inspector workforce declined by 20% between fiscal years 2018 and 2022, which paradoxically let sites operate with less documentation discipline because inspection probability was low. The BRIDGE pilot is designed to reverse that equation — more sites assessed, faster — and sites that staffed to the old probability curve are now exposed.
Sponsors will hear this as a site problem. It isn’t only that. A site that receives a one-day assessment finding tied to a sponsor-initiated protocol deviation — one that was issued without adequate site training, documented in an email thread rather than a formal protocol deviation notice — now has a shared liability the sponsor helped create. The ICH E6(R3) principle of sponsor oversight runs both directions: if you want sites to maintain inspection-ready documentation, the operational infrastructure to do it has to be funded in the contract.
What Changes Before the Next Knock
For site operators, the practical shift is this: stop treating inspection readiness as an event and start treating it as a steady-state operating standard. That means two specific things. First, the eISF audit cadence moves from quarterly to monthly — a coordinator-led completeness check against the TMF Reference Model that closes filing gaps before they compound. Second, every deviation log needs a standing reconciliation protocol: open deviations older than 30 days without a closed CAPA must trigger an automatic escalation to the site director, not just the study coordinator. These are not new GCP requirements. They are existing requirements that the one-day model will now actually test.
For sponsors and CROs, the immediate operational directive is to add a documentation readiness clause to every site qualification checklist — not a checkbox asking whether the site “has a TMF system” but a functional question: can this site produce any eISF document within two hours of a verbal request? If the answer requires more than one coordinator to execute, the site staffing model needs to be addressed in the budget negotiation before the SIV, not after a 483 arrives. A failed site costs between $150,000 and $300,000 in replacement startup costs, based on typical per-site contract and startup values — the incremental investment to keep documentation current is a fraction of that exposure.
The sites that will do well under BRIDGE are the ones that already behave as though an inspector is two weeks out at any given moment — not because of paranoia, but because continuous readiness is the only documentation discipline that actually holds when a coordinator turns over mid-study. The pilot is a signal about where FDA inspection strategy is heading. Sites that treat it as a one-time procedural adjustment will be caught. Sites that use it as a forcing function to build real-time documentation infrastructure will find themselves inspection-ready whether the FDA stays for one day or six.
References
- FiercePharma — “FDA rolls out 1-day assessment pilot in bid to refocus inspection resources”
- FDA.gov — “FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight” (April 2026)
- DCAT Value Chain Insights — “A Shortage of Inspectors Curtailing FDA Inspections: The Impact on Pharma”
- Starfish Medical — “FDA’s Inspection Process”
- U.S. Government Accountability Office — GAO-24-106383: FDA Clinical Research Inspector Workforce Decline, FY2018–2022
